Tudor Investment Corp ET AL cut its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 13.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,658 shares of the biopharmaceutical company’s stock after selling 6,889 shares during the period. Tudor Investment Corp ET AL owned approximately 0.10% of Vanda Pharmaceuticals worth $611,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after buying an additional 521,669 shares during the last quarter. State Street Corp raised its position in shares of Vanda Pharmaceuticals by 27.2% in the fourth quarter. State Street Corp now owns 1,751,605 shares of the biopharmaceutical company’s stock worth $27,935,000 after buying an additional 374,095 shares in the last quarter. FMR LLC raised its position in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Vanda Pharmaceuticals by 6.8% in the fourth quarter. Macquarie Group Ltd. now owns 1,372,640 shares of the biopharmaceutical company’s stock worth $21,894,000 after buying an additional 86,891 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Vanda Pharmaceuticals by 65.3% in the first quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock worth $13,150,000 after buying an additional 370,900 shares in the last quarter. 91.35% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded up 7.44% during trading on Thursday, reaching $16.60. 806,254 shares of the company’s stock were exchanged. The company’s market capitalization is $739.56 million. The company’s 50-day moving average is $15.89 and its 200-day moving average is $14.60. Vanda Pharmaceuticals Inc. has a 1-year low of $11.58 and a 1-year high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.18. The business had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm posted $0.01 earnings per share. Equities research analysts expect that Vanda Pharmaceuticals Inc. will post ($0.70) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Tudor Investment Corp ET AL Has $611,000 Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/03/vanda-pharmaceuticals-inc-nasdaqvnda-shares-sold-by-tudor-investment-corp-et-al-updated-updated-updated.html.

A number of brokerages have weighed in on VNDA. Piper Jaffray Companies set a $23.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. Oppenheimer Holdings, Inc. set a $21.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. HC Wainwright set a $18.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 18th. Finally, Jefferies Group LLC restated a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, May 25th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $21.22.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.